Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis.
A man with acute lymphoblastic leukaemia developed disseminated Scedosporium prolificans infection following chemotherapy for disease relapse while on posaconazole prophylaxis. Scedosporium prolificans infection during posaconazole prophylaxis has not been reported previously. This report is timely as the uptake of posaconazole, the broadest spectrum azole clinically available, is likely to grow with recent evidence supporting its role as prophylaxis against invasive fungal infections in high-risk haematology patients.
Ananda-Rajah
M R
MR
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, 3050, Australia. michelle.ananda-rajah@mh.org.au
Grigg
A
A
Slavin
M A
MA
D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D008271:Mycetoma / Q000209:etiology / Q000517:prevention & control*; D009894:Opportunistic Infections / Q000209:etiology / Q000517:prevention & control*; D011743:Pyrimidines / Q000008:administration & dosage*; D012008:Recurrence; D021681:Scedosporium; D014230:Triazoles / Q000008:administration & dosage*; D065819:Voriconazole
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D065819:Voriconazole